These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30573049)

  • 1. Genetic studies in the evaluation of myeloproliferative neoplasms.
    Caponetti GC; Bagg A
    Semin Hematol; 2019 Jan; 56(1):7-14. PubMed ID: 30573049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative syndromes: diagnosis and therapeutic options.
    Hellmann A
    Pol Arch Med Wewn; 2008 Dec; 118(12):756-60. PubMed ID: 19202955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders.
    Klippel S; Pahl HL
    Pathol Biol (Paris); 2004 Jun; 52(5):267-74. PubMed ID: 15217712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in myeloproliferative neoplasms - their significance and clinical use.
    Schischlik F; Kralovics R
    Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
    Vardiman J; Hyjek E
    Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine Modeling of Myeloproliferative Neoplasms.
    Chen K; Shih AH
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):253-265. PubMed ID: 33641867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
    Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.